Cosmos Health targets 2029 revenue of $200.6 million, gross profit of $71.2 million
COSM•Cosmos Health reiterated its 2029 targets of $200.6 million in revenue and $71.2 million in gross profit, citing contract manufacturing as a key driver.
1. Manufacturing pipeline
The company said Cana Laboratories’ contract manufacturing pipeline exceeded $20 million in implied revenue, with more than $18 million in implied gross profit at margins above 90%. Management estimated the current pipeline equates to about $5 million in annual revenue and $4.5 million in annual gross profit. The production pipeline reached 32.7 million units, about six times its mid-2024 level, supporting a goal of more than $10 million in recurring annual gross profit.
